Marc Weiner1,2, Jon Gelfond1, Teresa L Johnson-Pais1, Melissa Engle1, John L Johnson3,4, William C Whitworth5, Erin Bliven-Sizemore5, Pheona Nsubuga4, Susan E Dorman6, Rada Savic7. 1. University of Texas Health Science Center San Antonio, San Antonio, TX, USA. 2. South Texas Veterans Health Care System, San Antonio, TX, USA. 3. Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 4. Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda. 5. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6. Medical University of South Carolina, Charleston, SC, USA. 7. University of California San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: Rifapentine exposure is associated with bactericidal activity against Mycobacterium tuberculosis, but high interindividual variation in plasma concentrations is encountered. OBJECTIVES: To investigate a genomic association with interindividual variation of rifapentine exposure, SNPs of six human genes involving rifamycin metabolism (AADAC, CES2), drug transport (SLCO1B1, SLCO1B3) and gene regulation (HNF4A, PXR) were evaluated. METHODS: We characterized these genes in 173 adult participants in treatment trials of the Tuberculosis Trials Consortium. Participants were stratified by self-identified race (black or non-black), and rifapentine AUC from 0 to 24 h (AUC0-24) was adjusted by analysis of covariance for SNPs, rifapentine dose, sex, food and HIV coinfection. This study was registered at ClinicalTrials.gov under identifier NCT01043575. RESULTS: The effect on rifapentine least squares mean AUC0-24 in black participants overall decreased by -10.2% for AADAC rs1803155 G versus A allele (Wald test: P = 0.03; false discovery rate, 0.10). Black participants with one G allele in AADAC rs1803155 were three times as likely to have below target bactericidal rifapentine exposure than black participants with the A allele (OR, 2.97; 95% CI: 1.16, 7.58). With two G alleles, the OR was greater. In non-black participants, AADAC rs1803155 SNP was not associated with rifapentine exposure. In both black and non-black participants, other evaluated genes were not associated with rifapentine exposure (P > 0.05; false discovery rate > 0.10). CONCLUSIONS: Rifapentine exposure in black participants varied with AADAC rs1803155 genotype and the G allele was more likely to be associated with below bactericidal target rifapentine exposure. Further pharmacogenomic study is needed to characterize the association of the AADAC rs1803155 with inadequate rifapentine exposure in different patient groups. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Rifapentine exposure is associated with bactericidal activity against Mycobacterium tuberculosis, but high interindividual variation in plasma concentrations is encountered. OBJECTIVES: To investigate a genomic association with interindividual variation of rifapentine exposure, SNPs of six human genes involving rifamycin metabolism (AADAC, CES2), drug transport (SLCO1B1, SLCO1B3) and gene regulation (HNF4A, PXR) were evaluated. METHODS: We characterized these genes in 173 adult participants in treatment trials of the Tuberculosis Trials Consortium. Participants were stratified by self-identified race (black or non-black), and rifapentine AUC from 0 to 24 h (AUC0-24) was adjusted by analysis of covariance for SNPs, rifapentine dose, sex, food and HIV coinfection. This study was registered at ClinicalTrials.gov under identifier NCT01043575. RESULTS: The effect on rifapentine least squares mean AUC0-24 in black participants overall decreased by -10.2% for AADAC rs1803155 G versus A allele (Wald test: P = 0.03; false discovery rate, 0.10). Black participants with one G allele in AADAC rs1803155 were three times as likely to have below target bactericidal rifapentine exposure than black participants with the A allele (OR, 2.97; 95% CI: 1.16, 7.58). With two G alleles, the OR was greater. In non-black participants, AADAC rs1803155 SNP was not associated with rifapentine exposure. In both black and non-black participants, other evaluated genes were not associated with rifapentine exposure (P > 0.05; false discovery rate > 0.10). CONCLUSIONS: Rifapentine exposure in black participants varied with AADAC rs1803155 genotype and the G allele was more likely to be associated with below bactericidal target rifapentine exposure. Further pharmacogenomic study is needed to characterize the association of the AADAC rs1803155 with inadequate rifapentine exposure in different patient groups. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Geraldine M Clarke; Carl A Anderson; Fredrik H Pettersson; Lon R Cardon; Andrew P Morris; Krina T Zondervan Journal: Nat Protoc Date: 2011-02-03 Impact factor: 13.491
Authors: Simbarashe P Zvada; Jan-Stefan Van Der Walt; Peter J Smith; P Bernard Fourie; Giorgio Roscigno; Denis Mitchison; Ulrika S H Simonsson; Helen M McIlleron Journal: Antimicrob Agents Chemother Date: 2010-06-01 Impact factor: 5.191
Authors: Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405
Authors: Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon Journal: Clin Infect Dis Date: 2016-08-10 Impact factor: 9.079
Authors: Derek J Sloan; Andrew D McCallum; Alessandro Schipani; Deirdre Egan; Henry C Mwandumba; Steve A Ward; David Waterhouse; Gertrude Banda; Theresa J Allain; Andrew Owen; Saye H Khoo; Geraint R Davies Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Jose Francis; Simbarashe P Zvada; Paolo Denti; Mark Hatherill; Salome Charalambous; Stanley Mungofa; Rodney Dawson; Susan Dorman; Nikhil Gupte; Lubbe Wiesner; Amina Jindani; Thomas S Harrison; Adeniyi Olagunju; Deirdre Egan; Andrew Owen; Helen M McIlleron Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.938
Authors: Jan-Willem C Alffenaar; Tawanda Gumbo; Kelly E Dooley; Charles A Peloquin; Helen Mcilleron; Andre Zagorski; Daniela M Cirillo; Scott K Heysell; Denise Rossato Silva; Giovanni Battista Migliori Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079